|
1
|
Shin A, Kim KZ, Jung KW, Park S, Won YJ,
Kim J, Kim DY and Oh JH: Increasing trend of colorectal cancer
incidence in Korea, 1999–2009. Cancer Res Treat. 44:219–226. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jung KW, Won YJ, Kong HJ and Lee ES:
Prediction of cancer incidence and mortality in Korea, 2018. Cancer
Res Treat. 50:317–323. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
De Angelis R, Sant M, Coleman MP,
Francisci S, Baili P, Pierannunzio D, Trama A, Visser O, Brenner H,
Ardanaz E, et al: Cancer survival in Europe 1999–2007 by country
and age: Results of EUROCARE-5-a population-based study. Lancet
Oncol. 15:23–34. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mundade R, Imperiale TF, Prabhu L, Loehrer
PJ and Lu T: Genetic pathways, prevention, and treatment of
sporadic colorectal cancer. Oncoscience. 1:400–406. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Castagnola P and Giaretti W: Mutant KRAS,
chromosomal instability and prognosis in colorectal cancer. Biochim
Biophys Acta. 1756:115–125. 2005.PubMed/NCBI
|
|
6
|
Suehiro Y, Wong CW, Chirieac LR, Kondo Y,
Shen L, Webb CR, Chan YW, Chan AS, Chan TL, Wu TT, et al:
Epigenetic-genetic interactions in the APC/WNT, RAS/RAF, and P53
pathways in colorectal carcinoma. Clin Cancer Res. 14:2560–2569.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Malumbres M and Barbacid M: RAS oncogenes:
The first 30 years. Nat Rev Cancer. 3:459–465. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rosty C, Young JP, Walsh MD, Clendenning
M, Walters RJ, Pearson S, Pavluk E, Nagler B, Pakenas D, Jass JR,
et al: Colorectal carcinomas with KRAS mutation are associated with
distinctive morphological and molecular features. Mod Pathol.
26:825–834. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tanaka M, Omura K, Watanabe Y, Oda Y and
Nakanishi I: Prognostic factors of colorectal cancer: K-ras
mutation, overexpression of the p53 protein, and cell proliferative
activity. J Surg Oncol. 57:57–64. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kakar S, Aksoy S, Burgart LJ and Smyrk TC:
Mucinous carcinoma of the colon: Correlation of loss of mismatch
repair enzymes with clinicopathologic features and survival. Mod
Pathol. 17:696–700. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rimbert J, Tachon G, Junca A, Villalva C,
Karayan-Tapon L and Tougeron D: Association between
clinicopathological characteristics and RAS mutation in colorectal
cancer. Mod Pathol. 31:517–526. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Millar J: The Need for a Global
Language-SNOMED CT introduction. Stud Health Technol Inform.
225:683–685. 2016.PubMed/NCBI
|
|
13
|
Yang D, Lai X, Xu F, Li Y, Jiang W and Ma
D: Prognosis and clinical characteristics of colorectal cancer
patients with KRAS gene mutation: A 5-year follow-up study. Int J
Clin Exp Pathol. 12:409–418. 2019.PubMed/NCBI
|
|
14
|
Lim DR, Kuk JK, Kim T and Shin EJ:
Comparison of oncological outcomes of right-sided colon cancer
versus left-sided colon cancer after curative resection: Which side
is better outcome? Medicine (Baltimore). 96:e82412017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen CH, Hsieh MC, Hsiao PK, Lin EK, Lu YJ
and Wu SY: A critical reappraisal for the value of tumor size as a
prognostic variable in rectal adenocarcinoma. J Cancer.
8:1927–1934. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhai ZW and Gu J: Influence of tumor size
on the prognosis in patients with colon cancer. Zhonghua Wei Chang
Wai Ke Za Zhi. 15:495–498. 2012.(In Chinese). PubMed/NCBI
|
|
17
|
Oh SY, Han JY, Lee SR and Lee HT: Improved
DNA extraction method for molecular diagnosis from smaller numbers
of cells. Korean J Clin Lab Sci. 46:99–105. 2014. View Article : Google Scholar
|
|
18
|
Bosman FT, Carneiro F, Hruban RH and
Theise ND: WHO classification of tumours of the digestive system.
Fourth Edition. IARC. 2010.
|
|
19
|
Weiser MR: AJCC 8th edition: Colorectal
cancer. Ann Surg Oncol. 25:1454–1455. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Onodera M, Nishigami T, Torii I, Sato A,
Tao LH, Kataoka TR, Yoshikawa R and Tsujimura T: Comparison between
colorectal low- and high-grade mucinous adenocarcinoma with MUC1
and MUC5AC. World J Gastrointest Oncol. 1:69–73. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ueno H, Hashiguchi Y, Shimazaki H, Shinto
E, Kajiwara Y, Nakanishi K, Kato K, Maekawa K, Miyai K, Nakamura T,
et al: Objective criteria for crohn-like lymphoid reaction in
colorectal cancer. Am J Clin Pathol. 139:434–441. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shia J, Schultz N, Kuk D, Vakiani E,
Middha S, Segal NH, Hechtman JF, Berger MF, Stadler ZK, Weiser MR,
et al: Morphological characterization of colorectal cancers in The
Cancer Genome Atlas reveals distinct morphology-molecular
associations: Clinical and biological implications. Mod Pathol.
30:599–609. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Iseki Y, Shibutani M, Maeda K, Nagahara H,
Fukuoka T, Matsutani S, Kashiwagi S, Tanaka H, Hirakawa K and Ohira
M: A new method for evaluating tumor-infiltrating lymphocytes
(TILs) in colorectal cancer using hematoxylin and eosin
(H-E)-stained tumor sections. PLoS One. 13:e01927442018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lugli A, Kirsch R, Ajioka Y, Bosman F,
Cathomas G, Dawson H, El Zimaity H, Flèjou JF, Hansen TP, Hartmann
A, et al: Recommendations for reporting tumor budding in colorectal
cancer based on the International Tumor Budding Consensus
Conference (ITBCC) 2016. Mod Pathol. 30:1299–1311. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kruschewski M, Mueller K, Lipka S,
Budczies J, Noske A, Buhr HJ and Elezkurtaj S: The prognostic
impact of p53 expression on sporadic colorectal cancer is dependent
on p21 status. Cancers (Basel). 3:1274–1284. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ogino S, Kawasaki T, Kirkner GJ, Ogawa A,
Dorfman I, Loda M and Fuchs CS: Down-regulation of p21
(CDKN1A/CIP1) is inversely associated with microsatellite
instability and CpG island methylator phenotype (CIMP) in
colorectal cancer. J Pathol. 210:147–154. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Guo F, Gong H, Zhao H, Chen J, Zhang Y,
Zhang L, Shi X, Zhang A, Jin H, Zhang J and He Y: Mutation status
and prognostic values of KRAS, NRAS, BRAF and PIK3CA in 353 Chinese
colorectal cancer patients. Sci Rep. 8:60762018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lee WS, Lee JN, Baek JH and Park YH: RAS
status in Korean patients with stage III and IV colorectal cancer.
Clin Transl Oncol. 17:751–756. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Byun JH, Ahn JB, Kim SY, Kang JH, Zang DY,
Kang SY, Kang MJ, Shim BY, Baek SK, Kim BS, et al: The impact of
primary tumor location in patients with metastatic colorectal
cancer: A Korean Cancer Study Group CO12-04 study. Korean J Intern
Med. 34:165–177. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Calistri D, Rengucci C, Seymour I,
Leonardi E, Truini M, Malacarne D, Castagnola P and Giaretti W:
KRAS, p53 and BRAF gene mutations and aneuploidy in sporadic
colorectal cancer progression. Cell Oncol. 28:161–166.
2006.PubMed/NCBI
|
|
31
|
Tosi F, Magni E, Amatu A, Mauri G,
Bencardino K, Truini M, Veronese S, De Carlis L, Ferrari G,
Nichelatti M, et al: Effect of KRAS and BRAF mutations on survival
of metastatic colorectal cancer after liver resection: A systematic
review and meta-analysis. Clin Colorectal Cancer. 16:e153–e163.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bai B, Shan L, Xie B, Huang X, Mao W, Wang
X, Wang D and Zhu H: Mutations in KRAS codon 12 predict poor
survival in Chinese patients with metastatic colorectal cancer.
Oncol Lett. 15:3161–3166. 2018.PubMed/NCBI
|
|
33
|
Lee JH, Ahn J, Park WS, Choe EK, Kim E,
Shin R, Heo SC, Jung S, Kim K, Chai YJ and Chae H: Colorectal
cancer prognosis is not associated with BRAF and KRAS Mutations-A
STROBE compliant study. J Clin Med. 8(pii): E1112019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Payandeh M, Shazad B, Sadeghi M and
Shahbazi M: Correlation between RAS test results and prognosis of
metastatic colorectal cancer patients: A report from Western Iran.
Asian Pac J Cancer Prev. 17:1729–1732. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Modest DP, Brodowicz T, Stintzing S, Jung
A, Neumann J, Laubender RP, Ocvirk J, Kurteva G, Papai Z,
Knittelfelder R, et al: Impact of the specific mutation in KRAS
codon 12 mutated tumors on treatment efficacy in patients with
metastatic colorectal cancer receiving cetuximab-based first-line
therapy: A pooled analysis of three trials. Oncology. 83:241–247.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Renaud S, Guerrera F, Seitlinger J,
Costardi L, Schaeffer M, Romain B, Mossetti C, Claire-Voegeli A,
Filosso PL, Legrain M, et al: KRAS exon 2 codon 13 mutation is
associated with a better prognosis than codon 12 mutation following
lung metastasectomy in colorectal cancer. Oncotarget. 8:2514–2524.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Jones RP, Sutton PA, Evans JP, Clifford R,
McAvoy A, Lewis J, Rousseau A, Mountford R, McWhirter D and Malik
HZ: Specific mutations in KRAS codon 12 are associated with worse
overall survival in patients with advanced and recurrent colorectal
cancer. Br J Cancer. 116:923–929. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kaczirek K, Ciuleanu TE, Vrbanec D, Marton
E, Messinger D, Liegl-Atzwanger B, Wrba F, Knittelfelder R, Lindner
E, Zielinski CC, et al: FOLFOX4 plus cetuximab for patients with
previously untreated metastatic colorectal cancer according to
tumor RAS and BRAF mutation status: Updated analysis of the
CECOG/CORE 1.2.002 study. Clin Colorectal Cancer. 14:91–98. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yoon HH, Tougeron D, Shi Q, Alberts SR,
Mahoney MR, Nelson GD, Nair SG, Thibodeau SN, Goldberg RM, Sargent
DJ, et al: KRAS codon 12 and 13 mutations in relation to
disease-free survival in BRAF-wild-type stage III colon cancers
from an adjuvant chemotherapy trial (N0147 alliance). Clin Cancer
Res. 20:3033–3043. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kadowaki S, Kakuta M, Takahashi S,
Takahashi A, Arai Y, Nishimura Y, Yatsuoka T, Ooki A, Yamaguchi K,
Matsuo K, et al: Prognostic value of KRAS and BRAF mutations in
curatively resected colorectal cancer. World J Gastroenterol.
21:1275–1283. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Alberts SR, Sargent DJ, Nair S, Mahoney
MR, Mooney M, Thibodeau SN, Smyrk TC, Sinicrope FA, Chan E, Gill S,
et al: Effect of oxaliplatin, fluorouracil, and leucovorin with or
without cetuximab on survival among patients with resected stage
III colon cancer: A randomized trial. JAMA. 307:1383–1393. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lee DW, Kim KJ, Han SW, Lee HJ, Rhee YY,
Bae JM, Cho NY, Lee KH, Kim TY, Oh DY, et al: KRAS mutation is
associated with worse prognosis in stage III or high-risk stage II
colon cancer patients treated with adjuvant FOLFOX. Ann Surg Oncol.
22:187–194. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Blons H, Emile JF, Le Malicot K, Juliè C,
Zaanan A, Tabernero J, Mini E, Folprecht G, Van Laethem JL, Thaler
J, et al: Prognostic value of KRAS mutations in stage III colon
cancer: Post hoc analysis of the PETACC8 phase III trial dataset.
Ann Oncol. 25:2378–2385. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Won DD, Lee JI, Lee IK, Oh ST, Jung ES and
Lee SH: The prognostic significance of KRAS and BRAF mutation
status in Korean colorectal cancer patients. BMC Cancer.
17:4032017. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Gao XH, Yu GY, Hong YG, Lian W, Chouhan H,
Xu Y, Liu LJ, Bai CG and Zhang W: Clinical significance of multiple
gene detection with a 22-gene panel in formalin-fixed
paraffin-embedded specimens of 207 colorectal cancer patients. Int
J Clin Oncol. 24:141–152. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Natsume S, Yamaguchi T, Takao M, Iijima T,
Wakaume R, Takahashi K, Matsumoto H, Nakano D, Horiguchi SI,
Koizumi K and Miyaki M: Clinicopathological and molecular
differences between right-sided and left-sided colorectal cancer in
Japanese patients. Jpn J Clin Oncol. 48:609–618. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Inoue Y, Saigusa S, Iwata T, Okugawa Y,
Toiyama Y, Tanaka K, Uchida K, Mohri Y and Kusunoki M: The
prognostic value of KRAS mutations in patients with colorectal
cancer. Oncol Rep. 28:1579–1584. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Chang MH, Lee IK, Si Y, Lee KS, Woo IS and
Byun JH: Clinical impact of K-ras mutation in colorectal cancer
patients treated with adjuvant FOLFOX. Cancer Chemother Pharmacol.
68:317–323. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Kim HS, Heo JS, Lee J, Lee JY, Lee MY, Lim
SH, Lee WY, Kim SH, Park YA, Cho YB, et al: The impact of KRAS
mutations on prognosis in surgically resected colorectal cancer
patients with liver and lung metastases: A retrospective analysis.
BMC Cancer. 16:1202016. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Buim ME, Fanelli MF, Souza VS, Romero J,
Abdallah EA, Mello CA, Alves V, Ocea LM, Mingues NB, Barbosa PN, et
al: Detection of KRAS mutations in circulating tumor cells from
patients with metastatic colorectal cancer. Cancer Biol Ther.
16:1289–1295. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Cabrera-Mendoza F, Gainza-Lagunes S,
Castañeda-Andrade I and Castro-Zarate A: Clinical relevance of the
K-ras oncogene in colorectal cancer: Experience in a Mexican
population. Rev Gastroenterol Mex. 79:166–170. 2014.(In Spanish).
PubMed/NCBI
|
|
52
|
Zekri J, Rizvi A, Al-Maghrabi J and Bin
Sadiq B: K-ras in colorectal cancer tumors from saudi patients:
Frequency, Clinco-pathological Association and clinical outcome.
Open Colorectal Cancer J. 5:22–27. 2012. View Article : Google Scholar
|
|
53
|
Sastre J, Vidaurreta M, Gómez A, Rivera F,
Massutí B, López MR, Abad A, Gallen M, Benavides M, Aranda E, et
al: Prognostic value of the combination of circulating tumor cells
plus KRAS in patients with metastatic colorectal cancer treated
with chemotherapy plus bevacizumab. Clin Colorectal Cancer.
12:280–286. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Serenari M, Alvarez FA, Ardiles V, de
Santibañes M, Pekolj J and de Santibañes E: The ALPPS approach for
colorectal liver metastases: Impact of KRAS mutation status in
survival. Dig Surg. 35:303–310. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Graf W, Cashin PH, Ghanipour L, Enblad M,
Botling J, Terman A and Birgisson H: Prognostic impact of BRAF and
KRAS mutation in patients with colorectal and appendiceal
peritoneal metastases scheduled for CRS and HIPEC. Ann Surg Oncol.
27:293–300. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Winder T, Mündlein A, Rhomberg S,
Dirschmid K, Hartmann BL, Knauer M, Drexel H, Wenzl E, De Vries A
and Lang A: Different types of K-Ras mutations are conversely
associated with overall survival in patients with colorectal
cancer. Oncol Rep. 21:1283–1287. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
East JE, Atkin WS, Bateman AC, Clark SK,
Dolwani S, Ket SN, Leedham SJ, Phull PS, Rutter MD, Shepherd NA, et
al: British society of gastroenterology position statement on
serrated polyps in the colon and rectum. Gut. 66:1181–1196. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Lee CT, Huang YC, Hung LY, Chow NH, Su PF,
Ho CL, Tsai HW, Chen YL, Lin SC, Lin BW, et al: Serrated
adenocarcinoma morphology in colorectal mucinous adenocarcinoma is
associated with improved patient survival. Oncotarget.
8:35165–35175. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Patai AV, Molnár B, Tulassay Z and Sipos
F: Serrated pathway: Alternative route to colorectal cancer. World
J Gastroenterol. 19:607–615. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Loy TS and Kaplan PA: Villous
adenocarcinoma of the colon and rectum: A clinicopathologic study
of 36 cases. Am J Surg Pathol. 28:1460–1465. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Palazzo JP, Edmonston TB, Chaille-Arnold
LM and Burkholder S: Invasive papillary adenocarcinoma of the
colon. Hum Pathol. 33:372–375. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Gonzalez RS, Cates JM, Washington MK,
Beauchamp RD, Coffey RJ and Shi C: Adenoma-like adenocarcinoma: A
subtype of colorectal carcinoma with good prognosis, deceptive
appearance on biopsy and frequent KRAS mutation. Histopathology.
68:183–190. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Fecteau RE, Lutterbaugh J, Markowitz SD,
Willis J and Guda K: GNAS mutations identify a set of right-sided,
RAS mutant, villous colon cancers. PLoS One. 9:e879662014.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Kim MJ, Hong SM, Jang SJ, Yu E, Kim JS,
Kim KR, Gong G and Ro JY: Invasive colorectal micropapillary
carcinoma: An aggressive variant of adenocarcinoma. Hum Pathol.
37:809–815. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Pettinato G, Manivel CJ, Panico L, Sparano
L and Petrella G: Invasive micropapillary carcinoma of the breast:
Clinicopathologic study of 62 cases of a poorly recognized variant
with highly aggressive behavior. Am J Clin Pathol. 121:857–866.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Hendifar A, Yang D, Lenz F, Lurje G, Pohl
A, Lenz C, Ning Y, Zhang W and Lenz HJ: Gender disparities in
metastatic colorectal cancer survival. Clin Cancer Res.
15:6391–6397. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Majek O, Gondos A, Jansen L, Emrich K,
Holleczek B, Katalinic A, Nennecke A, Eberle A and Brenner H; GEKID
Cancer Survival Working Group, : Sex differences in colorectal
cancer survival: Population-based analysis of 164,996 colorectal
cancer patients in Germany. PLoS One. 8:e680772013. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Soulierès D, Greer W, Magliocco AM,
Huntsman D, Young S, Tsao MS and Kamel-Reid S: KRAS mutation
testing in the treatment of metastatic colorectal cancer with
anti-EGFR therapies. Curr Oncol. 17 (Suppl 1):S31–S40.
2010.PubMed/NCBI
|
|
69
|
Chuko J, Yeh MK, Chen BJ and Hu KY:
Efficacy of cetuximab on wild-type and mutant KRAS in colorectal
cancer: Systematic review and meta-analysis. J Med Sci. 30:189–198.
2010.
|
|
70
|
Pollheimer MJ, Kornprat P, Lindtner RA,
Harbaum L, Schlemmer A, Rehak P and Langner C: Tumor necrosis is a
new promising prognostic factor in colorectal cancer. Hum Pathol.
41:1749–1757. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Väyrynen SA, Väyrynen JP, Klintrup K,
Mäkelä J, Karttunen TJ, Tuomisto A and Mäkinen MJ: Clinical impact
and network of determinants of tumour necrosis in colorectal
cancer. Br J Cancer. 114:1334–1342. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Wikberg ML, Ling A, Li X, Öberg A, Edin S
and Palmqvist R: Neutrophil infiltration is a favorable prognostic
factor in early stages of colon cancer. Hum Pathol. 68:193–202.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Rao HL, Chen JW, Li M, Xiao YB, Fu J, Zeng
YX, Cai MY and Xie D: Increased intratumoral neutrophil in
colorectal carcinomas correlates closely with malignant phenotype
and predicts patients' adverse prognosis. PLoS One. 7:e308062012.
View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Sanz-Garcia E, Argiles G, Elez E and
Tabernero J: BRAF mutant colorectal cancer: Prognosis, treatment,
and new perspectives. Ann Oncol. 28:2648–2657. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Chen D, Huang JF, Liu K, Zhang LQ, Yang Z,
Chuai ZR, Wang YX, Shi DC, Huang Q and Fu WL: BRAFV600E mutation
and its association with clinicopathological features of colorectal
cancer: A systematic review and meta-analysis. PLoS One.
9:e906072014. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Davies H, Bignell GR, Cox C, Stephens P,
Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W,
et al: Mutations of the BRAF gene in human cancer. Nature.
417:949–954. 2002. View Article : Google Scholar : PubMed/NCBI
|
